MnVFC flu vaccine distribution is expected to begin next month. There are a few things you can do to prepare.
Now is a good time to clear out inventory from last season. Please report any expired flu doses from last season by selecting report nonviable vaccine in MIIC.
We recommend reviewing your prebook request by following the steps below:
- Login to MIIC.
- Go to the Vaccine Management header on the left-hand side.
- Select manage special event vaccine.
- From the Event dropdown select 2023-24 MnVFC pediatric influenza vaccine prebook.
If you have any questions about your prebook request, please contact us at health.mnvfc@state.mn.us.
To make sure all MnVFC providers have adequate flu vaccine early in the season, and because different brands and presentations become available at different times, you can expect to receive your prebook order in a few small shipments throughout the distribution season. We will send out a MnVFC announcement when distribution begins.
The federal government will no longer procure and distribute all COVID-19 vaccines in the country beginning in early August. The last opportunity for providers enrolled in the COVID-19 vaccine program to order vaccine is 3 p.m. on Aug 2. Providers should order enough vaccine to fulfill their needs through mid to late September when the authorization of the next formulation is expected. At that time, providers must be enrolled in the Vaccines for Children (VFC) and/or the Uninsured and Underinsured Adult Vaccine (UUAV) program to continue to serve people who meet program eligibility criteria. To provide COVID-19 vaccine to patients not eligible for VFC or UUAV, providers must purchase vaccine on the private market and be reimbursed through insurance.
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults. The Food and Drug Administration approved the first two vaccines for prevention of RSV lower respiratory tract disease (LRTD) for use in adults 60 years of age and older. The Advisory Committee on Immunization Practices recommended that persons 60 years and older may receive a single dose of RSV vaccine, using shared clinical decision-making.
For RSV vaccination, the decision should be based on a discussion between the health care provider and the patient, which might be guided by the patient’s risk for disease and their characteristics, values, and preferences; the provider’s clinical discretion; and the characteristics of the vaccine. As part of this discussion, providers and patients should consider the patient’s risk for severe RSV-associated disease. The RSV vaccines are 82 to 88% effective in preventing LRTD due to RSV.
Adverse events were similar across groups, however the GSK vaccine had more severe reactogenicity events than the Pfizer vaccine. Preliminary data shows there may be an increased risk of inflammatory neurologic events. Review the MMWR: Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices or package inserts for more information about adverse events.
Federal law requires anyone who vaccinates to give all patients, or their parents or legal guardians, the appropriate VIS before giving vaccines. Check your stock of VISs against this list. If you have outdated VISs, get current, printable versions at Immunize.org Vaccine Information Statements (VISs) CDC information sheets for patients.
Dates of Current VISs, as of July 24, 2023
*Updated or new
VIS
|
Current
|
Adenovirus
|
1/8/20
|
Anthrax
|
1/8/20
|
Cholera
|
10/30/19
|
Dengue
|
12/17/21
|
DTaP
|
8/6/21
|
Ebola
|
6/30/22
|
Hepatitis A
|
10/15/21
|
Hepatitis B*
|
5/12/23
|
Hib
|
8/6/21
|
HPV
|
8/6/21
|
Influenza
|
8/6/21
|
Japanese enceph
|
8/15/19
|
MenACWY
|
8/6/21
|
MenB
|
8/6/21
|
MMR
|
8/6/21
|
MMRV
|
8/6/21
|
Multi-vaccine*
|
7/24/23
|
PCV*
|
5/12/23
|
PPSV
|
10/30/19
|
Polio
|
8/6/21
|
Rabies
|
6/2/22
|
Rotavirus
|
10/15/21
|
RSV*
|
7/24/23
|
Smallpox/monkeypox
|
11/14/22
|
Td
|
8/6/21
|
Tdap
|
8/6/21
|
Typhoid
|
10/30/19
|
Varicella
|
8/6/21
|
Yellow fever
|
4/1/20
|
Zoster
|
2/4/22
|
|